Esra CANOOĞLU, Murat ABAY, Kutlay GÜRBULAK, Aytaç AKÇAY, Tayfur BEKYÜREK, Birgit SIST, Simone STEINER, Kadir Semih GÜMÜŞSOY

Investigation of the effcacy of Tarantula cubensis extract (Teranekron D6) in the treatment of subclinical and clinical mastitis in dairy cows

The aim of this study was to investigate the effects of the use of Teranekron alone or in combination with intramammaryantibiotic therapy for the treatment of subclinical and clinical mastitis on the recovery rate from mastitis. The study material wascomposed of 177 mammary lobes of 63 Holstein cows with subclinical (groups S1 and S2) and clinical mastitis (groups C1, C2, C3,and C4). In all of the treatment groups, excluding group S2, the California mastitis test scores were determined to have decreased afertreatment (P < 0.05). In groups C1, C2, C3, and C4, which were treated for clinical mastitis, the somatic cell count (SCC) values wereobserved to have decreased. The decrease in SCC values was statistically signifcant except in group C2 (P < 0.01). While the SCC valueswere observed to have decreased in group S1 (P > 0.05), which was treated with Teranekron alone, the same values were found to haveincreased in group S2, which was maintained for control purposes (P < 0.05). This study demonstrated that Teranekron D6 could beused as an alternative therapeutic for the treatment of clinical and subclinical mastitis, as it is authorized for the use in cattle with awithdrawal period of zero hours for meat and milk.

PDF

___

1. Seegers H, Fourichon C, Beaudeau F. Production efects related to mastitis and mastitis economics in dairy cattle herds. Vet Res 2003; 34: 475491.
2. Janzen JJ. Economic losses resulting from mastitis. A review. J Dairy Sci 1970; 53: 11511161.
3. Sandholm M, Matilla T. Biochemical aspects of bovine mastitis. Isr J Vet Med 1986; 42: 405415.
4. Sears PM, Heider LE. Detection of mastitis. Vet Clin North Am Large Anim Pract 1981; 3: 327346.
5. de Haas Y, Barkema HW, Schukken YF, Veerkamp RF. Associations between somatic cell count patterns and the incidence of clinical mastitis. Prev Vet Med 2005; 67: 5568.
6. Ziv G. Treatment of peracute and acute mastitis. Vet Clin North Am Food Anim Pract 1992; 8: 115.
7. Jones GF, Ward GE. Cause, occurrence, and clinical signs of mastitis and anorexia in cows in a Wisconsin study. J Am Vet Med Assoc 1989; 195: 11081113.
8. Quinn PJ, Carter ME, Markey BK, Carter GR. Clinical Veterinary Microbiology. London, UK: Wolfe Publishing; 1994.
9. Erskine RJ, Kirk JH, Tyler JW, DeGraves FJ. Advances in the therapy for mastitis. Vet Clin North Am Food Animal Pract 1993; 9: 499517.
10. Nair MK, Joy J, Vasudevan P, Hinckley L, Hoagland TA, Venkitanarayanan KS. Antibacterial efect of caprylic acid and monocaprylin on major bacterial mastitis pathogens. J Dairy Sci 2005; 88: 34883495.
11. Diarra MS, Petitclerc D, Lacasse P. Response of Staphylococcus aureus isolates from bovine mastitis to exogenous iron sources. J Dairy Sci 2002; 85: 21412148.
12. Oldham ER, Daley MJ. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J Dairy Sci 1991; 74: 41754182.
13. Hillerton JE, Semmens JE. Comparison of treatment of mastitis by oxytocin or antibiotics following detection according to changes in milk electrical conductivity prior to visible signs J Dairy Sci. 1999; 82: 9398.